Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
ADNOC Gas Targets Up to $4B Profit in 2026 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
PHOENIX, March 01, 2018 -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that company founder John N. Kapoor, Ph.D., has completed the previously announced formation of an independently controlled trust related to his ownership stake in the company. The trust has been publicly filed with the Securities and Exchange Commission by the company on a Current Report on Form 8-K.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
| CONTACT: | Corporate Communications | Investor Relations |
| Joe McGrath | Jackie Marcus or Chris Hodges | |
| INSYS Therapeutics | Alpha IR Group | |
| 480-500-3101 | 312-445-2870 | |
| [email protected] | [email protected] |
